| scholarly article | Q13442814 |
| P356 | DOI | 10.1093/JNCI/91.13.1154 |
| P8608 | Fatcat ID | release_ls6mnoeqtnhajfkeelgmhfpqte |
| P698 | PubMed publication ID | 10393724 |
| P5875 | ResearchGate publication ID | 12904968 |
| P50 | author | Christian Wittekind | Q29950649 |
| Kurt Engeland | Q39600946 | ||
| P2093 | author name string | A Tannapfel | |
| J Mössner | |||
| F Geissler | |||
| J Hauss | |||
| A Katalinic | |||
| K Krause | |||
| M Wasner | |||
| P2860 | cites work | Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers | Q29616471 |
| Clinical implications of the p53 tumor-suppressor gene | Q40865658 | ||
| The cyclin B2 promoter depends on NF-Y, a trimer whose CCAAT-binding activity is cell-cycle regulated | Q40965920 | ||
| p73 is a simian [correction of human] p53-related protein that can induce apoptosis | Q41091013 | ||
| Killer in search of a motive? | Q58987146 | ||
| P433 | issue | 13 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1154-1158 | |
| P577 | publication date | 1999-07-01 | |
| P1433 | published in | Journal of the National Cancer Institute | Q400279 |
| P1476 | title | Expression of p73 and its relation to histopathology and prognosis in hepatocellular carcinoma | |
| P478 | volume | 91 |
| Q51660356 | A naturally occurring p73 mutation in a p73-p53 double-mutant lung cancer cell line encodes p73 alpha protein with a dominant-negative function. |
| Q39458140 | A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain |
| Q35588857 | Aberrant expression of DeltaNp73 in benign and malignant tumours of the prostate: correlation with Gleason score |
| Q48345586 | Acquired expression of transcriptionally active p73 in hepatocellular carcinoma cells |
| Q44656396 | Alterations of DeltaTA-p 73 splice transcripts during melanoma development and progression |
| Q39662010 | Analysis of the intracellular localization of p73 N-terminal protein isoforms TAp73 and ∆Np73 in medulloblastoma cell lines |
| Q34747158 | Assessment of the Proliferative Marker Ki-67 and p53 Protein Expression in HBV- and HCV-related Hepatocellular Carcinoma Cases in Egypt. |
| Q79073712 | Clinicopathologic significance of genetic alterations in hepatocellular carcinoma |
| Q33219610 | Comparison of p63 and p73 expression in benign and malignant salivary gland lesions |
| Q92723439 | Comprehensive analysis of transcriptome profiles in hepatocellular carcinoma |
| Q42999479 | Dietary fat/cholesterol-sensitive PKCβ-RB signaling: Potential role in NASH/HCC axis |
| Q73800193 | Different expression of P14ARF defines two groups of breast carcinomas in terms of TP73 expression and TP53 mutational status |
| Q36351646 | Disruption of chromosomal locus 1p36 differentially modulates TAp73 and ΔNp73 expression in follicular lymphoma |
| Q35737349 | Early molecular and genetic determinants of primary liver malignancy |
| Q40491757 | Ectopic expression of p73alpha, but not p73beta, suppresses myogenic differentiation |
| Q26827810 | Evasion of anti-growth signaling: A key step in tumorigenesis and potential target for treatment and prophylaxis by natural compounds. |
| Q37825339 | Exploiting tyrosinase expression and activity in melanocytic tumors: quercetin and the central role of p53. |
| Q35011207 | Expression and clinical significance of TAp73alpha, p53, PCNA and apoptosis in hepatocellular carcinoma |
| Q53531338 | Expression of p53 and its homolog, p73, in HPV DNA positive oesophageal squamous cell carcinomas. |
| Q38290283 | Expression of p53 and its homologues in primary and recurrent squamous cell carcinomas of the head and neck |
| Q42471813 | Expression of p73 in normal skin and proliferative skin lesions |
| Q43086184 | Frequency of p16(INK4A) alterations and K-ras mutations in intrahepatic cholangiocarcinoma of the liver |
| Q28361986 | Frequent k- ras -2 mutations and p16(INK4A)methylation in hepatocellular carcinomas in workers exposed to vinyl chloride |
| Q34611410 | Genetic mechanisms of hepatocarcinogenesis |
| Q42996334 | Hepatic expression of the proliferative marker Ki-67 and p53 protein in HBV or HCV cirrhosis in relation to dysplastic liver cell changes and hepatocellular carcinoma |
| Q34512068 | Hepatocellular carcinoma--cause, treatment and metastasis |
| Q52544535 | INK4a-ARF alterations and p53 mutations in hepatocellular carcinomas. |
| Q37355478 | Identification of two contiguous minimally deleted regions on chromosome 1p36.31-p36.32 in oligodendroglial tumours |
| Q44124982 | Inactivation of retinoblastoma (RB) tumor suppressor by oncogenic isoforms of the p53 family member p73. |
| Q78357688 | Molecular pathogenesis of human hepatocellular carcinoma |
| Q43005729 | Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma |
| Q36055168 | N-(phosphonacetyl)-L-aspartate induces TAp73-dependent apoptosis by modulating multiple Bcl-2 proteins: potential for cancer therapy |
| Q52934103 | Overexpression of the p73 gene is a novel finding in high-risk B-cell chronic lymphocytic leukemia. |
| Q38291171 | Physical interaction with human tumor-derived p53 mutants inhibits p63 activities. |
| Q36288249 | Preclinical activity of combined HDAC and KDM1A inhibition in glioblastoma |
| Q33601945 | Quercetin abrogates chemoresistance in melanoma cells by modulating deltaNp73. |
| Q80531098 | Reduced expression of cell cycle regulator p18(INK4C) in human hepatocellular carcinoma |
| Q51825137 | Regulation of p38, PKC/Foxo3a/p73 signaling network by GTP during erythroid differentiation in chronic myelogenous leukemia. |
| Q53654881 | Regulation of telomerase activity by the p53 family member p73. |
| Q34541091 | Role of p73 in malignancy: tumor suppressor or oncogene? |
| Q38333551 | TAp63gamma can substitute for p53 in inducing expression of the maspin tumor suppressor. |
| Q38320453 | TAp73/Delta Np73 influences apoptotic response, chemosensitivity and prognosis in hepatocellular carcinoma. |
| Q35078717 | TP53 family members and human cancers |
| Q92091118 | TP73 is a credible biomarker for predicting clinical progression and prognosis in cervical cancer patients |
| Q38056849 | Tackling hepatitis B virus-associated hepatocellular carcinoma--the future is now. |
| Q40288057 | The gastrin gene promoter is regulated by p73 isoforms in tumor cells |
| Q35605993 | The p53R172H mutant does not enhance hepatocellular carcinoma development and progression. |
| Q34668320 | The prognostic molecular markers in hepatocellular carcinoma |
| Q24657943 | The relationship between metallothionein-1F (MT1F) gene and hepatocellular carcinoma |
| Q36430184 | The role of p53 protein family in gastrointestinal malignancies |
| Q36422865 | The role of p73 in hematological malignancies |
| Q45234812 | Thyroid status affects rat liver regeneration after partial hepatectomy by regulating cell cycle and apoptosis |
| Q53979470 | Transactivation-deficient Delta TA-p73 inhibits p53 by direct competition for DNA binding: implications for tumorigenesis. |
| Q74392070 | Wild type p73 overexpression and high-grade malignancy in breast cancer |
| Q74336181 | p16INK4A-alterations in primary angiosarcoma of the liver |
| Q34515770 | p53, p63 and p73--solos, alliances and feuds among family members |
| Q56928094 | p63 and p73 expression in extrahepatic bile duct carcinoma and their clinical significance |
| Q46307849 | p73 G4C14-to-A4T14 gene polymorphism and interaction with p53 exon 4 Arg72Pro on cancer susceptibility: a meta-analysis of the literature |
| Q44633578 | p73 can suppress the proliferation of cells that express mutant p53. |
| Q35103143 | p73 in Cancer. |
| Q28364918 | p73 is over-expressed in vulval cancer principally as the Delta 2 isoform |
| Q73520211 | p73 is up-regulated in a subset of hepatocellular carcinomas |
| Q45732686 | p73 overexpression and nuclear accumulation in hepatitis C virus-associated hepatocellular carcinoma |
| Q38294005 | p73 poses a barrier to malignant transformation by limiting anchorage-independent growth |
| Q34134990 | p73G4C14 to A4T14 polymorphism is associated with colorectal cancer risk and survival |
Search more.